2025 - Passed
North Dakota S.B. 2113
  • Creates a study that will examine non-opioid pharmacological treatment options and assess the use of existing opioid settlement funds. Additionally, the study will explore strategies to utilize these funds for the development and implementation of an education and awareness initiative regarding non-opioid pain management options.
2026 - Introduced
Ohio S.B. 434
  • Establishes the Verified Opioid and Intoxicant Consumer Education (VOICE) Act to require clear, evidence-based education on the risks of opioid, as well as available non-opioid pain management options, before patients begin or continue opioid therapy.
2025 - Introduced
Oklahoma H.B.1416
  • Ensures that a non-opioid drug approved by the FDA is not disadvantaged or discouraged with respect to coverage relative to an opioid for the treatment or management of pain on the state preferred drug list.
2026 - Introduced
Oklahoma S.B. 1563
  • Requires the state Medicaid program and regulated health plans cover FDA-approved non-opioid pain treatments without requiring patients to try opioids first and without less favorable coverage or higher cost-sharing than opioid treatments.
  • Prohibits Medicaid formularies and carrier utilization controls from disadvantaging clinically appropriate non-opioid pain treatments, such as through prior authorization or step therapy, compared to opioids.
  • Directs the state to leverage grants and opioid settlement funds to support education on non-opioid options.
2024 - Passed
Oklahoma S.B.1344
  • Requires that the state Medicaid preferred drug list and utilization management not disadvantage a non-opioid pain medication relative to an opioid pain medication.
  • Requires the state government to seek grant opportunities relating to education and services regarding non-opioid medications.
  • Provides that the state may assist in using opioid settlement funds to support education regarding non-opioid alternatives.
2025 - Passed
Oregon H.B. 3211
  • Requires the Oregon Health Authority to develop a non-opioid directive form.
2025 - Introduced
Oregon S.B.598
  • Requires health insurers and Medicaid establish parity for opioids and non-opioid treatments.
2026 - Introduced
Pennsylvania H.B. 2060/S.B. 1196
  • Requires Medicaid and commercial insurers to provide pain parity by ensuring FDA-approved non opioid drugs are not disadvantaged in coverage, cost sharing, or utilization controls compared with opioids, applying upon FDA approval.
2026 - Introduced
Rhode Island S.B. 3022/H.B. 2060
  • Requires health insurers to provide equal access to FDA-approved non-opioid pain medications, eliminating prior authorization and step therapy requirements that currently give opioids a prescribing advantage.
2025 - Introduced
South Carolina S.B. 161/H.B. 4165
  • Prohibits preferencing coverage of an opioid prescription treatment over a non-opioid treatment and requires the South Carolina Department of Public Health to create educational materials and guidelines for practitioners about non-opioid alternative treatment options.
2026 - Introduced
South Dakota H.B. 1085
  • Prohibits South Dakota insurers from denying coverage of a prescribed non-opioid medication in favor of an opioid.
  • Bars insurers from imposing stricter utilization controls or higher cost-sharing for non-opioid drugs than for clinically appropriate opioid or narcotic drugs.
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.